GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...
GlobalData on MSN13d
GSK and University of Oxford partner for cancer vaccine researchGSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates ...
Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by new patient starts across all regions. New blood cancer drug Ojjaara/Omjjara generated ...
Specialty medicines accounted for more than 80% of GSK's growth in 2024, led by oncology and respiratory immunology. Benlysta grew 14%, while Jemperli sales tripled, benefiting from expanded FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback